Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat

 - UBBFriend: Email this page to someone!    
Author Topic: ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®


Marietta, Ohio, April 14, 2021
ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP®.

For the development of this drug for DED to date the company has completed:
Ocular irritation studies
Proof of concept pre-clinical DED trials for efficacy
Confirmatory pre-clinical DED trials for efficacy
Pilot drug stability (ie. shelf-life) testing
Pilot tolerability and toxicology studies

All these studies were conducted by market-leading contract research organizations (CRO).

In order to progress to clinical trials, the Company intends to complete the following activities:
Complete topical application formulation(s)
Confirmatory DED efficacy tests
Drug product Good Lab Practice (GLP) IND-enabling safety toxicology
Communicate with Fedral Drug Administration (FDA) on clinical trial design criteria

Dry Eye Disease Market Overview
According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). The growth of dry eye related diseases may include several factors, such as aging, a decrease in the supportive hormones (ex. menopause), systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.

“This is a critical milestone in our application development and moves us forward to commercialization of ProtoKinetix’s Dry Eye Disease program.” – Clarence Smith, CEO President
See the promising research of AAGP® and results to date
Visit our new website at ProtoKinetix.com for more information and to join our email list.

Posts: 193 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share